We are live on
!
Find out more
6CM
683 Capital Management Portfolio holdings
AUM
$1.92B
1-Year Est. Return
85.52%
This Fund
S&P 500
This Quarter
Est. Return
+17.29%
1 Year Est. Return
+85.52%
3 Year Est. Return
+282.16%
5 Year Est. Return
+254.87%
10 Year Est. Return
+3,288.81%
AUM
$1.22B
AUM Growth
-$65.3M
(-5.1%)
Cap. Flow
-$208M
Cap. Flow
% of AUM
-16.99%
Top 10 Holdings %
Top 10 Hldgs %
34.8%
Holding
287
New
134
Increased
23
Reduced
46
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BorgWarner
BWA
|
+$20.6M |
| 2 |
Hilton Grand Vacations
HGV
|
+$19M |
| 3 |
Carvana
CVNA
|
+$12.5M |
| 4 |
NCR Atleos
NATL
|
+$9.39M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$6.39M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enova International
ENVA
|
+$28.6M |
| 2 |
FLG
Flagstar Bank National Association
FLG
|
+$24.5M |
| 3 |
Vistra
VST
|
+$18.3M |
| 4 |
Noble Corp
NE
|
+$16.1M |
| 5 |
Phinia Inc
PHIN
|
+$8.72M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.14% |
| 2 | Consumer Discretionary | 18.74% |
| 3 | Financials | 10.52% |
| 4 | Materials | 4.8% |
| 5 | Industrials | 3.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
PUT
Carvana
CVNA
$70.5B
| $14.8M | 1.21% |
1,400,000
-600,000
| -30% | -$4.49M |
|
27
Caesars Entertainment
CZR
$6.07B
| $14.5M | 1.19% |
310,000
-65,000
| -17% | -$2.89M |
|
|
28
Vistra
VST
$50.1B
| $14.4M | 1.18% |
375,000
-525,000
| -58% | -$18.3M |
|
|
MREO
29
Mereo BioPharma
MREO
$53.2M
| $14.3M | 1.17% |
6,200,000
+200,000
| +3% | +$383K |
|
30
Iovance Biotherapeutics
IOVA
$1.84B
| $14.2M | 1.17% |
1,750,000
-300,000
| -15% | -$1.57M |
|
31
Invivyd
IVVD
$166M
| $14.2M | 1.16% |
3,600,000
-400,000
| -10% | -$757K |
|
32
Cardlytics
CDLX
$23.2M
| $14.1M | 1.16% |
153,500
-22,507
| -13% | -$2.29M |
|
33
Garrett Motion
GTX
$5.82B
| $14.1M | 1.16% |
1,461,532
+61,532
| +4% | +$475K |
|
34
PUT
Alphabet (Google) Class C
GOOG
$4.57T
| $14.1M | 1.15% |
100,000
| – | – |
|
35
RXO
RXO
$3.35B
| $13.7M | 1.12% |
590,000
-60,000
| -9% | -$1.21M |
|
|
36
Noble Corp
NE
$6.49B
| $12M | 0.99% |
250,000
-344,900
| -58% | -$16.1M |
|
37
Valaris
VAL
$5.28B
| $12M | 0.98% |
175,000
-40,000
| -19% | -$2.74M |
|
38
Phathom Pharmaceuticals
PHAT
$712M
| $11.7M | 0.96% |
1,280,000
+180,000
| +16% | +$1.55M |
|
39
Immatics
IMTX
$1.15B
| $11.6M | 0.95% |
1,100,000
+20,000
| +2% | +$184K |
|
40
Viking Therapeutics
VKTX
$3.72B
| $11.5M | 0.95% |
620,000
-5,000
| -0.8% | -$65.4K |
|
41
uniQure
QURE
$2.96B
| $11.5M | 0.94% |
1,693,000
+118,000
| +7% | +$780K |
|
42
PUT
Citigroup
C
$221B
| $10.7M | 0.88% |
208,400
-41,600
| -17% | -$1.84M |
|
43
Harmony Biosciences
HRMY
$2.01B
| $10.5M | 0.86% |
325,000
-25,000
| -7% | -$698K |
|
|
APLS
44
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| $10.5M | 0.86% |
175,000
-401,000
| -70% | -$20.3M |
|
|
45
NCR Atleos
NATL
$3.51B
| $9.96M | 0.82% |
+410,000
| New | +$9.39M |
|
|
46
PUT
Noble Corp
NE
$6.49B
| $9.63M | 0.79% |
200,000
-100,000
| -33% | -$4.67M |
|
|
47
Sarepta Therapeutics
SRPT
$1.58B
| $8.35M | 0.68% |
86,600
+66,600
| +333% | +$6.39M |
|
|
CRESY
48
Cresud
CRESY
$798M
| $8.21M | 0.67% |
873,178
-552,579
| -39% | -$4.52M |
|
49
Sea Limited
SE
$66.5B
| $8.1M | 0.66% |
200,000
| – | – |
|
|
ITOS
50
DELISTED
iTeos Therapeutics
ITOS
| $7.83M | 0.64% |
715,000
-95,000
| -12% | -$942K |
|
Similar funds
QOP
RIL
MC
RCAG
BOH
DCM
CC
IAN
683 Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, 683 Capital Management held 287 positions worth $1.22B, down 5.1% from $1.29B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
683 Capital Management withdrew a net $208M in Q4 2023, closing 28 positions and reducing 46 holdings. Its most notable exit was Hess, an estimated $7.65M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 17% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, 683 Capital Management opened a new position in NCR Atleos worth $9.96M.
- 683 Capital Management's largest Q4 2023 buy was NCR Atleos: 410,000 shares worth $9.96M.
- 683 Capital Management added most to BorgWarner in Q4 2023, an estimated $20.6M increase.
- 683 Capital Management's biggest Q4 2023 reduction was Enova International, cutting an estimated $28.6M.
- 683 Capital Management fully exited Hess in Q4 2023, selling an estimated $7.65M.
- 683 Capital Management's ten largest holdings make up 35% of its $1.22B portfolio in Q4 2023.
- 683 Capital Management opened 134 new positions and closed 28 in Q4 2023.
- 683 Capital Management's portfolio value fell 5.1% quarter-over-quarter to $1.22B.
Based on 683 Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.